History
The journey of CUBEBIO since 2011
From establishment to global partnerships — milestones in early cancer diagnostics.
Milestone
2023
2023
- Signed a consignment production contract with Green Cross Medis
- Signed Research Collaboration Agreement with National Cancer Centre of Singapore (NCCS) and started collaborative research
- Selected as the 'Innovative Product' in Scouter Demo-day run by Korean governmental entity (Public Procurement Service)
- Achieved successful results in a pancreatic cancer clinical trial with SNUH
- Joining "CANCER MOONSHOT", US Government's initiative against cancer
2022
- Appointed as '2022 KOTRA startup global jump 300'
- Signed a joint technology development contract with SNUH
- Signed a joint technology development contract with Ewha Womans University Medical Center
- Selected as the new resident company at the Healthcare Innovation Park (HIP) of Seoul National University Hospital
- Selected as the company for Samsung Electronics technology sharing from Ministry of Trade, Industry and Energy: Patent Transfer [Patent Name: biosensor]
- Signed a USD 75.6 million worth export contract with the Jacobson Pharma Group, a listed pharmaceutical company in Hong Kong, for distribution in 8 countries
2021
- Received CE mark approval [CMDD-04M]
- Signed a contract with COSMAX Pharma for joint development of product and mass production
2020
- Participated in the 'ARABHEALTH 2020' held in Dubai, UAE with 96m² sized independent booth
- Celebrated the 20th anniversary of World Cancer Day as an official partner
- Obtained TI-3 rating as a result of technology evaluation conducted by NICE Information Service Co., Ltd.
- Obtained an export license (National Institute of Medical Device Safety Information) and a certificate of free sale (Korean Ministry of Food and Drug Safety)
- Awarded 2020 Korea Outstanding Bio Enterprise Award (Ministry of Trade, Industry and Energy, Ministry of Environment, and Ministry of Education)
- Signed a contract with FPA Co., Ltd. for joint development of the product and mass production
- 100% Acquisition of FPA Co., Ltd., a company specialized in automated equipment (As a subsidiary of CUBEBIO)
- Expansion of product line through introduction of Multi-Channel Automated Diagnostic Device, 'CMDD' series ('CMDD-20' for 20 people, 'CMDD-12' for 12 people, 'CMDD-04' for 4 people)
- Additional acquisition of ISO 13485:2016 (Certificate of International Medical Devices Quality Management System) (Institute of Global Certification)
- Received the first purchase order worth USD 15 million from 《Standart-Biotest》 LLC in Russia
- Signed a contract with OnCureXo Pte., a US-based company (To be expanded after pilot operation at McDonald's stores in Egypt, Saudi Arabia, Malaysia, and Indonesia)
- Raised capital from ACA Partners Pte Ltd, a Singapore-based multinational investment company
- Awarded the Companion Prize from 'World Class Middle Market & Small-Giant Enterprise Awards'
- First shipment of CMDD-04M, ordering model of 《Standart-Biotest》 LLC, to Russia for localization
- CUBEBIO localized the production of 'Biosensor', a core component of the Sensor Kit
2019
- Awarded the Korean Patent Grand Prize
- Obtained approval for sales of Class II in vitro diagnostics from the Chinese FDA (沈阳阿一生物科技有限公司)
- Signed a contract with Yongchenghanyuan (永成汉源), a China/Hong Kong-based large asset management company, with regard to investments and listing on the NASDAQ
- Signed a contract with Samsung Securities Co., Ltd., as a lead underwriter
- Signed a Patron partnership agreement with Union for International Cancer Control (UICC)
- Signed a 'Cancer Early Detection and Self-Diagnosis' program agreement with UICC
- Awarded the 2019 Moneytoday Grand Prize for Innovative Technology
- Signed a contract for the export of the Products (Cancer self-diagnostic device) worth USD 3 billion over a 5-year period with 《Standart-Biotest》 LLC in Russia
- Awarded the Global Top Technology Grand Prize at the 2019 World Class Small-Mighty Enterprise Award
- Participated in the UICC-led World Cancer Leaders' Summit in Kazakhstan as a Patron partner
- Signed a contract for mass production with BHflex and DKT
2017
- Obtained a medical device manufacturing business license, a medical device manufacturing license, and an export license for medical devices (Korean Ministry of Food and Drug Safety)
2015
- Certified as a company-affiliated research center
- Certified as a venture business
2014
- Attracted investments worth USD 2.5 million from Development Bank CB
2011
- Established CUBEBIO Co., Ltd.